Fragile X–Associated Tremor/Ataxia Syndrome (FXTAS) — Disease Characteristics Research Report

Target Disease

• Disease name: Fragile X–associated tremor/ataxia syndrome (FXTAS)
• Category: Mendelian / repeat-expansion disorder (X-linked; FMR1 premutation)
• MONDO ID: MONDO:0010382 (OpenTargets) (OpenTargets Search: Fragile X-associated tremor/ataxia syndrome,fragile X-associated tremor ataxia syndrome,FXTAS)

Executive overview (current understanding)

FXTAS is a late-onset, progressive neurodegenerative disorder that occurs in carriers of FMR1 premutation alleles and is classically characterized by action/intention tremor and cerebellar gait ataxia, with frequent cognitive decline and neuropsychiatric symptoms. The canonical genetic definition used in clinical trials and reviews is 55–200 CGG repeats in the 5′ untranslated region (5′UTR) of FMR1, with pathogenesis primarily attributed to toxic gain-of-function of elevated FMR1 mRNA and additional contributions from repeat-associated non-AUG (RAN) translation (e.g., FMRpolyG) and downstream proteostasis, mitochondrial, and glial/white-matter dysfunction (berry‐kravis2007fragilex‐associatedtremorataxia pages 1-2, bourgeois2026comprehensivemultidisciplinarycare pages 1-2, tassone2023insightandrecommendations pages 6-8).

1. Disease information

1.1 Definition / overview

• Landmark clinical/genetic testing guidance describes FXTAS as “a neurodegenerative disorder with core features of action tremor and cerebellar gait ataxia” with frequent associated parkinsonism and executive dysfunction/dementia; MRI often shows the middle cerebellar peduncle (MCP) sign; neuropathology shows ubiquitin-positive intranuclear inclusions in neurons and astrocytes (Berry-Kravis et al., 2007; DOI: https://doi.org/10.1002/mds.21493; Oct 2007) (berry‐kravis2007fragilex‐associatedtremorataxia pages 1-2, berry‐kravis2007fragilex‐associatedtremorataxia pages 7-8).

1.2 Key identifiers

A structured identifier summary is provided here:

Table: This table summarizes key identifiers and naming conventions for fragile X-associated tremor/ataxia syndrome, including ontology and OMIM references plus the causal gene. It is useful for harmonizing disease records across clinical, genomic, and knowledge-base resources.

Notes on missing codes: Orphanet, ICD-10/ICD-11, and an authoritative MeSH-browser identifier were not retrievable from the full-text/trial-record evidence available in this run; these should be added from dedicated ontology services in a separate curation step.

1.3 Synonyms / alternative names

Common synonyms used in the scientific and clinical-trial literature include: - Fragile X tremor ataxia syndrome - Fragile X-associated tremor ataxia syndrome - FXTAS (OpenTargets Search: Fragile X-associated tremor/ataxia syndrome,fragile X-associated tremor ataxia syndrome,FXTAS, NCT02936531 chunk 2).

1.4 Evidence sources (patient-level vs aggregated)

• Aggregated disease resources / reviews: e.g., Movement Disorders testing guidelines (2007) and later expert reviews/consensus statements (berry‐kravis2007fragilex‐associatedtremorataxia pages 1-2, tassone2023insightandrecommendations pages 6-8).
• Primary human data: postmortem molecular profiling (snRNA-seq) (dias2023glialdysregulationin pages 1-2), postmortem pathology/biochemistry (alvarezmora2023explorationofsumo23 pages 1-2).
• Clinical trial registry records: interventional and observational trial metadata (NCT records) (NCT00584948 chunk 1, NCT02603926 chunk 1).

2. Etiology

2.1 Primary causal factors

• Genetic cause: FXTAS occurs in FMR1 premutation carriers, typically defined as 55–200 CGG repeats in the 5′UTR of FMR1 (Berry-Kravis et al., 2007; DOI: https://doi.org/10.1002/mds.21493) (berry‐kravis2007fragilex‐associatedtremorataxia pages 1-2) and reiterated in clinical trial descriptions (NCT02936531 chunk 1).
• Core mechanistic etiology: an early synthesis states “The pathogenic mechanism is related to overexpression and toxicity of the FMR1 mRNA per se.” (Berry-Kravis et al., 2007; DOI: https://doi.org/10.1002/mds.21493) (berry‐kravis2007fragilex‐associatedtremorataxia pages 1-2).

2.2 Risk factors

Non-modifiable - Age: typical onset ~60 years in males, later in females; male penetrance rises steeply with age (berry‐kravis2007fragilex‐associatedtremorataxia pages 1-2, bourgeois2026comprehensivemultidisciplinarycare pages 1-2). - Sex: males are more frequently and more severely affected (bourgeois2026comprehensivemultidisciplinarycare pages 1-2). - Repeat size: higher CGG repeat number is associated with earlier onset in classic clinical synthesis (berry‐kravis2007fragilex‐associatedtremorataxia pages 1-2).

Potential genetic modifiers - AQP4 variants: a 2023 case-control modifier study found no significant association between common AQP4 SNPs/haplotypes and FXTAS development in 95 FXTAS vs 65 no-FXTAS premutation carriers (Frontiers in Aging Neuroscience; Jan 2023; DOI: https://doi.org/10.3389/fnagi.2022.1073258) (eliasmas2023evaluationofaqp4 pages 1-2). - Somatic instability / DNA repair genes: A 2023 premutation consensus report highlights somatic expansion processes and notes DNA repair genes such as FAN1 and MSH3 can modify expansion risk in premutation-associated conditions, contributing to phenotypic variability and informing counseling (Cells; Sep 2023; DOI: https://doi.org/10.3390/cells12182330) (tassone2023insightandrecommendations pages 6-8).

Environmental / exposure modifiers (limited evidence in retrieved set) - A multidisciplinary review notes exposures such as excessive alcohol and/or opioids can worsen white-matter hyperintensities (WMH) (bourgeois2026comprehensivemultidisciplinarycare pages 3-4).

2.3 Protective factors

Robust protective factors are not established in the retrieved primary literature. Some experimental/early therapeutic approaches aim to mitigate downstream oxidative/mitochondrial stress (see Treatment section), but these are not proven protective factors at the population level (pagano2024mitochondrialdysfunctionin pages 1-2).

2.4 Gene–environment interactions

Direct gene–environment interaction studies were not present in the retrieved evidence. The available review-level evidence suggests that toxic exposures may exacerbate white matter injury in genetically susceptible premutation carriers (bourgeois2026comprehensivemultidisciplinarycare pages 3-4).

3. Phenotypes

A structured phenotype table with HPO suggestions, onset/course, and numeric notes is provided here:

Table: This table summarizes the main clinical and imaging phenotypes of fragile X-associated tremor/ataxia syndrome, with suggested HPO mappings, typical onset and progression, and key numeric estimates useful for knowledge-base curation.

3.1 Natural history and progression (key data)

A cohort analysis reported the typical progression sequence and timing (male premutation carriers with FXTAS), with median times from first motor symptom: ataxia 2 years, falls 6 years, walking-aid dependence 15 years, death 21 years (Leehey et al., Movement Disorders; Jan 2007; DOI: https://doi.org/10.1002/mds.21252) (leehey2007progressionoftremor pages 2-4). The same progression metrics are reiterated in testing-guideline synthesis (berry‐kravis2007fragilex‐associatedtremorataxia pages 7-8).

3.2 Quality-of-life impact (high-level)

FXTAS progression leads to increasing gait instability, falls, need for assistive devices, and frequent evolution to major neurocognitive disorder/dementia in a substantial proportion of males, implying major impacts on independence and caregiver burden (bourgeois2026comprehensivemultidisciplinarycare pages 2-3, berry‐kravis2007fragilex‐associatedtremorataxia pages 7-8).

4. Genetic / molecular information

4.1 Causal gene

• FMR1 (fragile X messenger ribonucleoprotein 1) is the primary and essentially exclusive established disease gene for FXTAS in OpenTargets disease-target evidence (OpenTargets Search: Fragile X-associated tremor/ataxia syndrome,fragile X-associated tremor ataxia syndrome,FXTAS).

4.2 Pathogenic variant class

• Repeat expansion (trinucleotide): premutation 55–200 CGG repeats in the 5′UTR (berry‐kravis2007fragilex‐associatedtremorataxia pages 1-2, NCT02936531 chunk 1).
• Mechanistic consequence: increased FMR1 mRNA with toxic gain-of-function; inclusions in neurons and astrocytes (berry‐kravis2007fragilex‐associatedtremorataxia pages 1-2, bourgeois2026comprehensivemultidisciplinarycare pages 3-4).

4.3 Epigenetics / chromatin effects (selected primary/model evidence)

A Drosophila and patient-cell study reported increased histone acetylation at the FMR1 locus in premutation carriers and showed that chromatin-modifying interventions can suppress CGG-repeat induced neurodegeneration in models: “overexpressing any of three histone deacetylases (HDACs 3, 6, or 11) suppresses CGG repeat–induced neurodegeneration” and HAT inhibitors repressed FMR1 mRNA and extended fly lifespan (PLoS Genet; Dec 2010; DOI: https://doi.org/10.1371/journal.pgen.1001240) (todd2010histonedeacetylasessuppress pages 1-2).

4.4 Modifier genes

• Negative evidence: AQP4 common variants not associated with FXTAS development (eliasmas2023evaluationofaqp4 pages 1-2).
• Premutation consensus: DNA repair genes (e.g., FAN1, MSH3) may influence somatic repeat instability and thereby modulate phenotype variability (tassone2023insightandrecommendations pages 6-8).

5. Environmental information

FXTAS is not infectious and has no known infectious trigger in the retrieved evidence. Potential exposure-related worsening of white matter changes is noted in review-level evidence (excessive alcohol/opioids) (bourgeois2026comprehensivemultidisciplinarycare pages 3-4). More systematic environmental epidemiology for FXTAS was not available in the retrieved corpus.

6. Mechanism / pathophysiology

A structured mechanism table with GO/CL/UBERON suggestions is provided here:

Table: This table summarizes the main proposed pathophysiologic mechanisms in fragile X-associated tremor/ataxia syndrome, linking molecular players to evidence type, quantitative findings, and suggested ontology terms. It is useful for building structured disease knowledge-base entries across mechanism, cell type, and anatomy fields.

6.1 Recent developments (prioritizing 2023–2024)

Human brain cell-type evidence (2023): - A PNAS study performed single-nucleus RNA-seq of >120,000 nuclei from frontal cortex and cerebellum in 7 premutation carriers vs 6 controls, identifying cell-type-, region-, and disease-specific transcriptional perturbations with notable dysregulation in the cortical oligodendrocyte lineage (May 2023; DOI: https://doi.org/10.1073/pnas.2300052120) (dias2023glialdysregulationin pages 1-2).

Proteostasis/autophagy and inclusion biology (2023): - A Cells study examined human postmortem brain and patient fibroblasts, reporting SUMO2/3 conjugate positivity in FXTAS brains and findings consistent with impaired autophagic flux (p62/autophagosome accumulation) and downregulated autophagy-related GO terms (Sep 2023; DOI: https://doi.org/10.3390/cells12192364) (alvarezmora2023explorationofsumo23 pages 1-2).

Mitochondrial dysfunction / oxidative stress (2024): - A 2024 minireview highlights mitochondrial dysfunction as a convergent mechanism in FXTAS and discusses antioxidants/mitochondrial nutrients (ALA, carnitine, CoQ10) as therapeutic candidates; it notes a small open-label allopregnanolone study in six males showing reduced oxidative stress and improved mitochondrial function (Apr 2024; DOI: https://doi.org/10.1007/s11033-024-09415-7) (pagano2024mitochondrialdysfunctionin pages 1-2).

Consensus mechanistic framework (2023 conference synthesis): - A 2023 conference consensus article summarizes three nonexclusive upstream mechanisms for premutation-associated conditions: R-loops, RNA gain-of-function (RNA foci/gelation and sequestration of CGG-binding proteins), and RAN translation yielding potentially toxic proteins; it states these “contribute to subsequent consequences, including mitochondrial dysfunction and neuronal death” (Sep 2023; DOI: https://doi.org/10.3390/cells12182330) (tassone2023insightandrecommendations pages 6-8).

6.2 Causal chain (high-level)

A coherent causal chain supported by the retrieved evidence is: 1) FMR1 CGG premutation expansion → 2) elevated/abnormal FMR1 mRNA and/or RAN translation products (FMRpolyG) → 3) protein sequestration, nuclear inclusions, UPS/autophagy impairment, mitochondrial dysfunction/oxidative stress and glial/white-matter disruption → 4) cerebellar and fronto-subcortical circuit dysfunction → 5) clinical syndrome of tremor, ataxia, executive dysfunction/dementia, neuropsychiatric symptoms, neuropathy/autonomic dysfunction (berry‐kravis2007fragilex‐associatedtremorataxia pages 1-2, alvarezmora2023explorationofsumo23 pages 1-2, dias2023glialdysregulationin pages 1-2, todd2010histonedeacetylasessuppress pages 1-2).

7. Anatomical structures affected

Primary system: nervous system (brain; cerebellar and white-matter tracts). - Key neuroanatomy / UBERON suggestions: - Cerebellum (UBERON:0002037) - Middle cerebellar peduncle (UBERON:0001950) - Corpus callosum (UBERON:0001885) - Frontal lobe/cortex (UBERON:0001870)

Imaging and neuropathology emphasize white matter disease and the MCP sign, with broad distribution of neuronal and astrocytic inclusions (berry‐kravis2007fragilex‐associatedtremorataxia pages 7-8, bourgeois2026comprehensivemultidisciplinarycare media 7c781a75).

8. Temporal development

• Typical onset: after age 50, commonly around ~60 years in males (berry‐kravis2007fragilex‐associatedtremorataxia pages 1-2, NCT02936531 chunk 1).
• Course: progressive; cohort-based milestone progression includes falls and eventual dependence and death over a multi-year to multi-decade course (leehey2007progressionoftremor pages 2-4).
• Staging: A six-stage framework (from subtle symptoms to profound disability) is presented in the multidisciplinary review’s staging table (Table 2), with diagnostic categorization in Table 1 (bourgeois2026comprehensivemultidisciplinarycare media 7c781a75, bourgeois2026comprehensivemultidisciplinarycare media 4ec0dbb2).

9. Inheritance and population

9.1 Inheritance pattern

• X-linked via FMR1 premutation alleles; FXTAS manifests in premutation carriers with reduced penetrance, especially in females (bourgeois2026comprehensivemultidisciplinarycare pages 1-2).

9.2 Epidemiology and penetrance (statistics)

Premutation carrier frequency (population): - Estimated premutation prevalence reported as approximately 1 in 148–200 females and 1 in 290–855 males (Frontiers in Neurology review; Mar 2026; DOI: https://doi.org/10.3389/fneur.2026.1746002) (bourgeois2026comprehensivemultidisciplinarycare pages 1-2). - Earlier clinical synthesis reported carrier frequencies around 1/259 females and 1/813 males (Movement Disorders 2007) (berry‐kravis2007fragilex‐associatedtremorataxia pages 1-2).

FXTAS penetrance among premutation carriers: - A widely cited estimate: about 40% of male carriers >50 develop FXTAS; age-stratified male penetrance reported as 17% (50–59), 38% (60–69), 47% (70–79), 75% (80+) (berry‐kravis2007fragilex‐associatedtremorataxia pages 1-2). - Female penetrance is lower (often cited ~14–20% depending on cohort/source) (bourgeois2026comprehensivemultidisciplinarycare pages 1-2, tassone2023insightandrecommendationsa pages 18-20).

Disease prevalence in general population: - FXTAS prevalence has been estimated at ~2–4 per 100,000, based on cohort synthesis (leehey2007progressionoftremor pages 1-2).

10. Diagnostics

10.1 Genetic testing

• Diagnosis relies on DNA-based FMR1 CGG repeat sizing; the same fragile X DNA test is used in FXS and FXTAS evaluation (berry‐kravis2007fragilex‐associatedtremorataxia pages 7-8).

10.2 Clinical criteria (radiologic + clinical)

• A commonly used scheme defines Definite / Probable / Possible FXTAS based on combinations of major/minor radiologic signs (notably MCP/brainstem white-matter lesions) and clinical signs (notably intention tremor and gait ataxia). The multidisciplinary review reproduces these criteria in Table 1 (bourgeois2026comprehensivemultidisciplinarycare media 7c781a75).

10.3 Imaging

• MCP sign: “increased T2 signal intensity in the middle cerebellar peduncles” is a key radiologic hallmark (berry‐kravis2007fragilex‐associatedtremorataxia pages 7-8) and illustrated in the review’s MRI figure (bourgeois2026comprehensivemultidisciplinarycare media d690cd70).

10.4 Differential diagnosis

FXTAS is frequently mistaken for essential tremor, Parkinson disease, multiple system atrophy-cerebellar type (MSA-C), or spinocerebellar ataxias; testing guidelines recommend considering FMR1 testing in unexplained adult-onset tremor/ataxia or suggestive MRI findings (berry‐kravis2007fragilex‐associatedtremorataxia pages 7-8, eliasmas2023evaluationofaqp4 pages 1-2).

11. Outcomes / prognosis

• Progression milestones: median 2y to ataxia, 6y to falls, 15y to walking aid dependence, and 21y to death from initial motor symptom in cohort analysis (leehey2007progressionoftremor pages 2-4).
• Survival variability: survival after onset reported as variable (5–25 years) in the same synthesis (leehey2007progressionoftremor pages 2-4).

Complications include recurrent falls, progressive disability, and cognitive decline/dementia in a substantial fraction of males (bourgeois2026comprehensivemultidisciplinarycare pages 2-3, leehey2007progressionoftremor pages 2-4).

12. Treatment

12.1 Current clinical management (real-world implementation)

There is no established disease-modifying therapy in the retrieved evidence; care is largely symptom- and function-focused with multidisciplinary involvement. A multidisciplinary care review lists commonly used symptomatic agents (e.g., primidone, gabapentin/pregabalin, beta blockers for tremor; carbidopa/levodopa for parkinsonism; acetylcholinesterase inhibitors or memantine for cognitive symptoms) and emphasizes PT/OT/SLP, exercise, delirium-risk minimization, and caregiver support (Frontiers in Neurology; Mar 2026; DOI: https://doi.org/10.3389/fneur.2026.1746002) (bourgeois2026comprehensivemultidisciplinarycare pages 6-7).

MAXO suggestions (examples): - MAXO:0000004 pharmacotherapy - MAXO:0000015 physical therapy - MAXO:0000016 occupational therapy - MAXO:0000017 speech therapy - MAXO:0000757 genetic counseling

12.2 Clinical trials / experimental interventions

A structured trial table is provided here:

Table: This table summarizes the main FXTAS interventional and observational studies available in the retrieved ClinicalTrials.gov context, along with a real-world multidisciplinary management row. It is useful for quickly comparing study design, enrollment, outcomes, and implementation details across current FXTAS interventions.

Key trials with retrievable registry details include: - Memantine RCT (NCT00584948; completed; n=94; primary outcomes BDS-II executive function and CATSYS tremor) (NCT00584948 chunk 1). - Allopregnanolone (NCT02603926; open-label phase 2; completed; n=6; cognitive/tremor/MRI outcomes) (NCT02603926 chunk 1). - Sulforaphane (NCT05233579; open-label; completed; n=15; includes MRI lesion volumetrics and functional outcomes) (NCT05233579 chunk 2).

13. Prevention

Primary prevention of FXTAS is not currently possible in premutation carriers, but secondary/tertiary prevention strategies include: - Genetic counseling and cascade testing when FXTAS or other fragile X–associated conditions are identified in a family (berry‐kravis2007fragilex‐associatedtremorataxia pages 7-8). - Risk factor mitigation for complications (e.g., fall prevention, management of psychiatric symptoms, and avoidance of exposures that may worsen white-matter disease per expert review) (bourgeois2026comprehensivemultidisciplinarycare pages 3-4).

14. Other species / natural disease

Naturally occurring FXTAS as a spontaneous veterinary condition was not identified in the retrieved evidence.

15. Model organisms (key systems)

FXTAS is extensively studied in Drosophila, mouse (CGG knock-in and inducible CGG-expression models), and cell-based systems.

15.1 Drosophila models

• A Neuron study reported that “transcribed premutation repeats alone are sufficient to cause neurodegeneration” and that Purα overexpression “could suppress rCGG-mediated neurodegeneration in a dose-dependent manner” (Aug 2007; DOI: https://doi.org/10.1016/j.neuron.2007.07.020) (jin2007purαbinds pages 1-2).
• Epigenetic modulation in flies: overexpressing HDAC3/6/11 suppresses CGG-repeat neurodegeneration and HAT inhibitors reduce FMR1 mRNA in premutation cells and extend fly lifespan (Dec 2010; DOI: https://doi.org/10.1371/journal.pgen.1001240) (todd2010histonedeacetylasessuppress pages 1-2).

15.2 Mouse models

• A 2014 review summarizes that mouse models recapitulate elevated Fmr1 mRNA, reduced FMRP, ubiquitin-positive intranuclear inclusions, dendritic abnormalities, memory and motor deficits, and RAN-translation-related pathology; it provides population-frequency and penetrance estimates for context (Jul 2014; DOI: https://doi.org/10.1186/1866-1955-6-25) (berman2014mousemodelsof pages 1-3).
• An inducible mouse model study reported that stopping expanded-CGG expression early could reverse inclusion formation and ameliorate motor phenotypes; it also reports inclusions stain for FMRpolyG (Jun 2015; DOI: https://doi.org/10.1093/hmg/ddv216) (hukema2015reversibilityofneuropathology pages 1-2).

15.3 Cell-based / iPSC-derived systems

• A mechanistic study in models links RAN translation → FMRpolyG → UPS impairment, with suppression by HSP70 and attenuation by preventing RAN translation (May/Aug 2015; DOI: https://doi.org/10.1093/hmg/ddv165) (oh2015rantranslationat pages 1-2).

Evidence gaps and curation notes

1. ICD-10/ICD-11, Orphanet (ORPHA), and authoritative MeSH ID: not retrievable from the current evidence set; should be added via dedicated ontology services.
2. 2023–2024 interventional outcomes: ClinicalTrials.gov records in this run provide trial structure but not full numeric efficacy results; linking to results publications (e.g., Seritan et al. 2014 for memantine) is recommended for outcome extraction (NCT00584948 chunk 1).

Key figure/table evidence used

• Diagnostic criteria and staging tables, and MRI example of MCP sign were retrieved from the multidisciplinary review (bourgeois2026comprehensivemultidisciplinarycare media 7c781a75, bourgeois2026comprehensivemultidisciplinarycare media 4ec0dbb2, bourgeois2026comprehensivemultidisciplinarycare media d690cd70).

References

1. (OpenTargets Search: Fragile X-associated tremor/ataxia syndrome,fragile X-associated tremor ataxia syndrome,FXTAS): Open Targets Query (Fragile X-associated tremor/ataxia syndrome,fragile X-associated tremor ataxia syndrome,FXTAS, 3 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (berry‐kravis2007fragilex‐associatedtremorataxia pages 1-2): Elizabeth Berry‐Kravis, Liane Abrams, Sarah M. Coffey, Deborah A. Hall, Claudia Greco, Louise W. Gane, Jim Grigsby, James A. Bourgeois, Brenda Finucane, Sebastien Jacquemont, James A. Brunberg, Lin Zhang, Janet Lin, Flora Tassone, Paul J. Hagerman, Randi J. Hagerman, and Maureen A. Leehey. Fragile x‐associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Movement Disorders, 22:2018-2030, Oct 2007. URL: https://doi.org/10.1002/mds.21493, doi:10.1002/mds.21493. This article has 399 citations and is from a highest quality peer-reviewed journal.

3. (bourgeois2026comprehensivemultidisciplinarycare pages 1-2): James A. Bourgeois, Andrea Schneider, Jessica Klusek, Thomas R. Christensen, Ellie Levin, Kendall Gardner, Ariel A. Jacobi, and Randi J. Hagerman. Comprehensive, multidisciplinary care for fragile x-associated tremor/ataxia syndrome. Frontiers in Neurology, Mar 2026. URL: https://doi.org/10.3389/fneur.2026.1746002, doi:10.3389/fneur.2026.1746002. This article has 0 citations and is from a peer-reviewed journal.

4. (tassone2023insightandrecommendations pages 6-8): Flora Tassone, Dragana Protic, Emily Graves Allen, Alison D Archibald, Anna Baud, Ted W Brown, Dejan B Budimirovic, Jonathan Cohen, Brett Dufour, Rachel Eiges, Nicola Elvassore, Lidia V Gabis, Samantha J Grudzien, Deborah A Hall, David Hessl, Abigail Hogan, Jessica Ezzell Hunter, Peng Jin, Poonnada Jiraanont, Jessica Klusek, R Frank Kooy, Claudine M Kraan, Cecilia Laterza, Andrea Lee, Karen Lipworth, Molly Losh, Danuta Loesch-Mdzewska, Reymundo Lozano, Marsha R Mailick, Apostolos Manolopoulos, Veronica Martinez-Cerdeno, Yingratana McLennan, Robert M Miller, Federica Alice Maria Montanaro, Matthew W Mosconi, Sarah Nelson Potter, Melissa Raspa, Susan M Rivera, Katharine Shelly, Peter K Todd, Katarzyna Tutak, Jun Yi Wang, Anne Wheeler, Tri Indah Winarni, Marwa Zafarullah, and Randi J Hagerman. Insight and recommendations for fragile x-premutation-associated conditions from the fifth international conference on fmr1 premutation. Cells, Sep 2023. URL: https://doi.org/10.3390/cells12182330, doi:10.3390/cells12182330. This article has 81 citations.

5. (berry‐kravis2007fragilex‐associatedtremorataxia pages 7-8): Elizabeth Berry‐Kravis, Liane Abrams, Sarah M. Coffey, Deborah A. Hall, Claudia Greco, Louise W. Gane, Jim Grigsby, James A. Bourgeois, Brenda Finucane, Sebastien Jacquemont, James A. Brunberg, Lin Zhang, Janet Lin, Flora Tassone, Paul J. Hagerman, Randi J. Hagerman, and Maureen A. Leehey. Fragile x‐associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Movement Disorders, 22:2018-2030, Oct 2007. URL: https://doi.org/10.1002/mds.21493, doi:10.1002/mds.21493. This article has 399 citations and is from a highest quality peer-reviewed journal.

6. (eliasmas2023evaluationofaqp4 pages 1-2): Andrea Elias-Mas, Miriam Potrony, Jaume Bague, David J. Cutler, Maria Isabel Alvarez-Mora, Teresa Torres, Tamara Barcos, Joan Anton Puig-Butille, Marta Rubio, Irene Madrigal, Susana Puig, Emily G. Allen, and Laia Rodriguez-Revenga. Evaluation of aqp4 functional variants and its association with fragile x-associated tremor/ataxia syndrome. Frontiers in Aging Neuroscience, Jan 2023. URL: https://doi.org/10.3389/fnagi.2022.1073258, doi:10.3389/fnagi.2022.1073258. This article has 6 citations and is from a peer-reviewed journal.

7. (alvarezmora2023explorationofsumo23 pages 1-2): Maria Isabel Alvarez-Mora, Glòria Garrabou, Laura Molina-Porcel, Ruben Grillo-Risco, Francisco Garcia-Garcia, Tamara Barcos, Judith Cantó-Santos, and Laia Rodriguez-Revenga. Exploration of sumo2/3 expression levels and autophagy process in fragile x-associated tremor/ataxia syndrome: addressing study limitations and insights for future research. Cells, 12:2364, Sep 2023. URL: https://doi.org/10.3390/cells12192364, doi:10.3390/cells12192364. This article has 4 citations.

8. (NCT02936531 chunk 2): Dr. Sharon Hassin. Brain Network Activation and Gait and Posture in FXTAS. Sheba Medical Center. 2016. ClinicalTrials.gov Identifier: NCT02936531

9. (NCT02936531 chunk 1): Dr. Sharon Hassin. Brain Network Activation and Gait and Posture in FXTAS. Sheba Medical Center. 2016. ClinicalTrials.gov Identifier: NCT02936531

10. (dias2023glialdysregulationin pages 1-2): Caroline M. Dias, Biju Issac, Liang Sun, Abigail Lukowicz, Maya Talukdar, Shyam K. Akula, Michael B. Miller, Katherine Walsh, Shira Rockowitz, and Christopher A. Walsh. Glial dysregulation in the human brain in fragile x-associated tremor/ataxia syndrome. Proceedings of the National Academy of Sciences of the United States of America, May 2023. URL: https://doi.org/10.1073/pnas.2300052120, doi:10.1073/pnas.2300052120. This article has 26 citations and is from a highest quality peer-reviewed journal.

11. (liani2025premutationfemaleswith pages 4-6): Valentina Liani, Carme Torrents, Elisa Rolleri, Nor Azyati Yusoff, Narueporn Likhitweerawong, Sydney Moore, Flora Tassone, Andrea Schneider, Ellery Santos, Hazel M. B. Biag, James A. Bourgeois, Kathryn E. Unruh, Matthew W. Mosconi, and Randi J. Hagerman. Premutation females with prefxtas. International Journal of Molecular Sciences, 26:2825, Mar 2025. URL: https://doi.org/10.3390/ijms26062825, doi:10.3390/ijms26062825. This article has 10 citations.

12. (bourgeois2026comprehensivemultidisciplinarycare pages 6-7): James A. Bourgeois, Andrea Schneider, Jessica Klusek, Thomas R. Christensen, Ellie Levin, Kendall Gardner, Ariel A. Jacobi, and Randi J. Hagerman. Comprehensive, multidisciplinary care for fragile x-associated tremor/ataxia syndrome. Frontiers in Neurology, Mar 2026. URL: https://doi.org/10.3389/fneur.2026.1746002, doi:10.3389/fneur.2026.1746002. This article has 0 citations and is from a peer-reviewed journal.

13. (NCT00584948 chunk 1): Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome. University of California, Davis. 2007. ClinicalTrials.gov Identifier: NCT00584948

14. (NCT02603926 chunk 1): Randi J. Hagerman, MD. Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone. Randi J. Hagerman, MD. 2015. ClinicalTrials.gov Identifier: NCT02603926

15. (bourgeois2026comprehensivemultidisciplinarycare pages 3-4): James A. Bourgeois, Andrea Schneider, Jessica Klusek, Thomas R. Christensen, Ellie Levin, Kendall Gardner, Ariel A. Jacobi, and Randi J. Hagerman. Comprehensive, multidisciplinary care for fragile x-associated tremor/ataxia syndrome. Frontiers in Neurology, Mar 2026. URL: https://doi.org/10.3389/fneur.2026.1746002, doi:10.3389/fneur.2026.1746002. This article has 0 citations and is from a peer-reviewed journal.

16. (pagano2024mitochondrialdysfunctionin pages 1-2): Giovanni Pagano, Alex Lyakhovich, Federico V. Pallardó, Luca Tiano, Adriana Zatterale, and Marco Trifuoggi. Mitochondrial dysfunction in fragile x syndrome and fragile x-associated tremor/ataxia syndrome: prospect use of antioxidants and mitochondrial nutrients. Molecular Biology Reports, Apr 2024. URL: https://doi.org/10.1007/s11033-024-09415-7, doi:10.1007/s11033-024-09415-7. This article has 12 citations and is from a peer-reviewed journal.

17. (bourgeois2026comprehensivemultidisciplinarycare pages 4-6): James A. Bourgeois, Andrea Schneider, Jessica Klusek, Thomas R. Christensen, Ellie Levin, Kendall Gardner, Ariel A. Jacobi, and Randi J. Hagerman. Comprehensive, multidisciplinary care for fragile x-associated tremor/ataxia syndrome. Frontiers in Neurology, Mar 2026. URL: https://doi.org/10.3389/fneur.2026.1746002, doi:10.3389/fneur.2026.1746002. This article has 0 citations and is from a peer-reviewed journal.

18. (berry‐kravis2007fragilex‐associatedtremorataxia pages 2-4): Elizabeth Berry‐Kravis, Liane Abrams, Sarah M. Coffey, Deborah A. Hall, Claudia Greco, Louise W. Gane, Jim Grigsby, James A. Bourgeois, Brenda Finucane, Sebastien Jacquemont, James A. Brunberg, Lin Zhang, Janet Lin, Flora Tassone, Paul J. Hagerman, Randi J. Hagerman, and Maureen A. Leehey. Fragile x‐associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Movement Disorders, 22:2018-2030, Oct 2007. URL: https://doi.org/10.1002/mds.21493, doi:10.1002/mds.21493. This article has 399 citations and is from a highest quality peer-reviewed journal.

19. (bourgeois2026comprehensivemultidisciplinarycare pages 2-3): James A. Bourgeois, Andrea Schneider, Jessica Klusek, Thomas R. Christensen, Ellie Levin, Kendall Gardner, Ariel A. Jacobi, and Randi J. Hagerman. Comprehensive, multidisciplinary care for fragile x-associated tremor/ataxia syndrome. Frontiers in Neurology, Mar 2026. URL: https://doi.org/10.3389/fneur.2026.1746002, doi:10.3389/fneur.2026.1746002. This article has 0 citations and is from a peer-reviewed journal.

20. (bourgeois2026comprehensivemultidisciplinarycare media 7c781a75): James A. Bourgeois, Andrea Schneider, Jessica Klusek, Thomas R. Christensen, Ellie Levin, Kendall Gardner, Ariel A. Jacobi, and Randi J. Hagerman. Comprehensive, multidisciplinary care for fragile x-associated tremor/ataxia syndrome. Frontiers in Neurology, Mar 2026. URL: https://doi.org/10.3389/fneur.2026.1746002, doi:10.3389/fneur.2026.1746002. This article has 0 citations and is from a peer-reviewed journal.

21. (leehey2007progressionoftremor pages 2-4): Maureen A. Leehey, Elizabeth Berry‐Kravis, Sung‐Joon Min, Deborah A. Hall, Cathlin D. Rice, Lin Zhang, Jim Grigsby, Claudia M. Greco, Ann Reynolds, Rebecca Lara, Jennifer Cogswell, Sebastien Jacquemont, David R. Hessl, Flora Tassone, Randi Hagerman, and Paul J. Hagerman. Progression of tremor and ataxia in male carriers of the fmr1 premutation. Movement Disorders, 22:203-206, Jan 2007. URL: https://doi.org/10.1002/mds.21252, doi:10.1002/mds.21252. This article has 171 citations and is from a highest quality peer-reviewed journal.

22. (todd2010histonedeacetylasessuppress pages 1-2): Peter K. Todd, Seok Yoon Oh, Amy Krans, Udai B. Pandey, Nicholas A. Di Prospero, Kyung-Tai Min, J. Paul Taylor, and Henry L. Paulson. Histone deacetylases suppress cgg repeat–induced neurodegeneration via transcriptional silencing in models of fragile x tremor ataxia syndrome. PLoS Genetics, 6:e1001240, Dec 2010. URL: https://doi.org/10.1371/journal.pgen.1001240, doi:10.1371/journal.pgen.1001240. This article has 114 citations and is from a domain leading peer-reviewed journal.

23. (bourgeois2026comprehensivemultidisciplinarycare media 4ec0dbb2): James A. Bourgeois, Andrea Schneider, Jessica Klusek, Thomas R. Christensen, Ellie Levin, Kendall Gardner, Ariel A. Jacobi, and Randi J. Hagerman. Comprehensive, multidisciplinary care for fragile x-associated tremor/ataxia syndrome. Frontiers in Neurology, Mar 2026. URL: https://doi.org/10.3389/fneur.2026.1746002, doi:10.3389/fneur.2026.1746002. This article has 0 citations and is from a peer-reviewed journal.

24. (tassone2023insightandrecommendationsa pages 18-20): F Tassone, D Protic, E Allen, AD Archibald, and A Baud. Insight and recommendations for fragile x premutation associated conditions from the 5th international conference on fmr1 premutation. Unknown journal, 2023.

25. (leehey2007progressionoftremor pages 1-2): Maureen A. Leehey, Elizabeth Berry‐Kravis, Sung‐Joon Min, Deborah A. Hall, Cathlin D. Rice, Lin Zhang, Jim Grigsby, Claudia M. Greco, Ann Reynolds, Rebecca Lara, Jennifer Cogswell, Sebastien Jacquemont, David R. Hessl, Flora Tassone, Randi Hagerman, and Paul J. Hagerman. Progression of tremor and ataxia in male carriers of the fmr1 premutation. Movement Disorders, 22:203-206, Jan 2007. URL: https://doi.org/10.1002/mds.21252, doi:10.1002/mds.21252. This article has 171 citations and is from a highest quality peer-reviewed journal.

26. (bourgeois2026comprehensivemultidisciplinarycare media d690cd70): James A. Bourgeois, Andrea Schneider, Jessica Klusek, Thomas R. Christensen, Ellie Levin, Kendall Gardner, Ariel A. Jacobi, and Randi J. Hagerman. Comprehensive, multidisciplinary care for fragile x-associated tremor/ataxia syndrome. Frontiers in Neurology, Mar 2026. URL: https://doi.org/10.3389/fneur.2026.1746002, doi:10.3389/fneur.2026.1746002. This article has 0 citations and is from a peer-reviewed journal.

27. (NCT05233579 chunk 2): Open-Label Trial of Sulforaphane in Premutation Carriers With FXTAS. University of California, Davis. 2021. ClinicalTrials.gov Identifier: NCT05233579

28. (NCT04428567 chunk 2): Treadmill Training in Fragile X-associated Tremor/Ataxia Syndrome. Rush University Medical Center. 2019. ClinicalTrials.gov Identifier: NCT04428567

29. (jin2007purαbinds pages 1-2): Peng Jin, Ranhui Duan, Abrar Qurashi, Yunlong Qin, Donghua Tian, Tracie C. Rosser, Huijie Liu, Yue Feng, and Stephen T. Warren. Pur α binds to rcgg repeats and modulates repeat-mediated neurodegeneration in a drosophila model of fragile x tremor/ataxia syndrome. Neuron, 55:556-564, Aug 2007. URL: https://doi.org/10.1016/j.neuron.2007.07.020, doi:10.1016/j.neuron.2007.07.020. This article has 363 citations and is from a highest quality peer-reviewed journal.

30. (berman2014mousemodelsof pages 1-3): Robert F Berman, Ronald AM Buijsen, Karen Usdin, Elizabeth Pintado, Frank Kooy, Dalyir Pretto, Isaac N Pessah, David L Nelson, Zachary Zalewski, Nicholas Charlet-Bergeurand, Rob Willemsen, and Renate K Hukema. Mouse models of the fragile x premutation and fragile x-associated tremor/ataxia syndrome. Journal of Neurodevelopmental Disorders, Jul 2014. URL: https://doi.org/10.1186/1866-1955-6-25, doi:10.1186/1866-1955-6-25. This article has 87 citations and is from a peer-reviewed journal.

31. (hukema2015reversibilityofneuropathology pages 1-2): Renate K. Hukema, Ronald A.M. Buijsen, Martijn Schonewille, Chris Raske, Lies-Anne W.F.M. Severijnen, Ingeborg Nieuwenhuizen-Bakker, Rob F.M. Verhagen, Lisanne van Dessel, Alex Maas, Nicolas Charlet-Berguerand, Chris I. De Zeeuw, Paul J. Hagerman, Robert F. Berman, and Rob Willemsen. Reversibility of neuropathology and motor deficits in an inducible mouse model for fxtas. Human molecular genetics, 24 17:4948-57, Jun 2015. URL: https://doi.org/10.1093/hmg/ddv216, doi:10.1093/hmg/ddv216. This article has 61 citations and is from a domain leading peer-reviewed journal.

32. (oh2015rantranslationat pages 1-2): Seok Yoon Oh, Fang He, Amy Krans, Michelle Frazer, J. Paul Taylor, Henry L. Paulson, and Peter K. Todd. Ran translation at cgg repeats induces ubiquitin proteasome system impairment in models of fragile x-associated tremor ataxia syndrome. Human molecular genetics, 24 15:4317-26, Aug 2015. URL: https://doi.org/10.1093/hmg/ddv165, doi:10.1093/hmg/ddv165. This article has 112 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02
• Edison artifact artifact-03